In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Minister Calls For More Drug Production In Vietnam

This article was originally published in PharmAsia News

Executive Summary

Vietnam's health minister called for an effort to manufacture more pharmaceuticals in the country to make it less dependent on imports. Nguyen Quoc Trieu said his ministry and the Ministry of Industry want more factories to be built to produce antibiotics for the local market. Deputies of each of the ministries said building drug-making plants is a top priority of the country. Half of the medicines sold in Vietnam are produced in the country, but they usually are commonly used drugs. Only a few manufacturers are able to make drugs to treat difficult diseases. The country also imports 90 percent of its drug ingredients. (Click here for more

You may also be interested in...

Teva Sees COVID Sales Correction

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Could ChromaDex’ Tru Niagen Block Coronavirus Infection?

In vitro data shows potential for Chromadex' Tru Niagen dietary supplement to block coronavirus infection. Chromadex' CEO Rob Fried tells HBW Insight about the company's background and Tru Niagen's recent UK launch. 

Pipeline Watch: Phase III Readouts For Seladelpar, Fasinumab And Carbetocin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts